China NMPA Drug Inspection - Zhong Sheng Tang Pharmacy, Huantan Town, Sui County - Licorice tablets

The Hebei Provincial Drug Administration issued a quality bulletin on December 23, 2021, detailing failures discovered during its annual sampling and inspection program. The report identifies Anguo Jiuwang Pharmaceutical Co., Ltd. as having produced substandard licorice tablets (Batch No. 20122607). Testing conducted by the Hengshui Comprehensive Inspection and Testing Center confirmed that these products failed the 'content determination' requirement, indicating that the active ingredient levels did not meet established quality standards. Samples were collected from retail and community healthcare providers, including Zhong Sheng Tai Pharmacy and the Donghu Community Health Service Station. Governed by the Drug Administration Law of the People's Republic of China, the regulatory framework mandates immediate corrective and punitive measures. Authorities have already moved to seize and seal the non-compliant batches to prevent further distribution. Required actions include the formal investigation and prosecution of the manufacturer for producing substandard drugs, the implementation of risk control protocols, and the public disclosure of final enforcement results within three months. Additionally, any evidence of counterfeit activity must be referred to the public security department for criminal prosecution. These efforts ensure the integrity of the pharmaceutical supply chain and protect public health through strict regulatory oversight.